# Syncona Ltd Creation of leading retinal gene therapy platform

- Link: https://www.directorstalkinterviews.com/syncona-ltd-creation-of-leading-retinal-gene-therapy-platform/412771751
- Published: 2019-04-11T07:21:38+01:00
- Author: Charlotte Edwards

**Syncona Ltd** (LON:SYNC), a leading healthcare company focused on founding, building
and funding global leaders in life science, today announces the merger of its companies,
Gyroscope Therapeutics (Gyroscope), an ophthalmology company developing genetically
defined therapies for retinal diseases and Orbit Biomedical (Orbit), a specialist
medical device company focused on precision sub-retinal therapeutic delivery. Syncona
will own 82% of the enlarged company (a holding value of £28.9 million), which will
retain the Gyroscope name.

The merger creates the first fully integrated retinal gene therapy company with 
high quality manufacturing and a surgical platform that can support accurate, safe
and consistent sub-retinal delivery of treatments to patients with blinding conditions.

> **Chris Hollowood, Chief Investment Officer of Syncona and Chair of Gyroscope,
> said**: “Gyroscope is one of the first companies globally to move gene therapy
> out of rare diseases through the delivery of natural regulatory proteins. As retinal
> gene therapy progresses to more prevalent conditions, delivering a therapeutic
> in a way that ensures higher consistency of dosing, whilst allowing patients to
> receive a less invasive treatment, is key to widespread use and clinical effectiveness.
> The merger ensures Gyroscope now has the key platform capabilities it requires
> to develop and deliver its therapeutics commercially. This marks an important 
> step in fulfilling founding academics, David Kavanagh and Andrew Lotery’s vision
> of widespread use of genetically defined treatments for dry AMD.”

As it enters its next phase of growth towards commercial development, the merged
group will be led by newly appointed CEO, Khurem Farooq. Khurem most recently held
the position of Senior Vice President of the Business Unit Immunology & Ophthalmology
at Genentech, where, notably, he was responsible for managing the commercial success
of Lucentis and the pre-launch activities for Lampalizumab. Soraya Bekkali, who 
has led Gyroscope into the clinic, will continue to lead the research and development
organisation as President, Head of R&D, whilst Mike Keane and Susan Hill, who led
the founding and launch of Orbit, will become Gyroscope’s Chief Technology Officer
and Chief Business Officer respectively.

Additionally, Ian Clark, who most recently served as Chief Executive of Genentech,
has been appointed as a Non-Executive Director.

Gyroscope has provided further information in its press release which can be found
here: http://gyroscopetx.com/press-releases/.

 

Share on:
